neomycin/polymyxin B/ bacitracin/lidocaine (OTC)

Frequency Not Defined

Allergic contact dermatitis

Contraindications

Hypersensitivity

Cautions

Ototoxicity and nephrotoxicity possible if treating large surface area or chronic use

Lidocaine may be significantly absorbed from mucosal surfaces and open wounds

Pregnancy category: C

Lactation: unknown if neomycin, polymyxin B, or bacitracin excreted in breast milk; systemic absorption of topical lidocaine has been reported

Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Neomycin, polymyxin B, and bacitracin elicit bacteriostatic activity

Lidocaine provides local anesthetic effect